478 Real-world outcomes in patients with penile squamous cell carcinoma (pSCC) receiving immune checkpoint inhibitors (ICI)

Abstract

Background Penile squamous cell carcinoma (pSCC) is a rare and aggressive neoplasm with poor outcomes in advanced set-tings and limited treatment options beyond TIP chemotherapy (paclitaxel/ifosfamide/cisplatin). We evaluated real-world outcomes in patients treated with immune checkpoint inhibitors (ICI) for pSCC. Methods We performed a retrospective review of patients with pSCC who received ICI from 2012-2022 at the Winship Cancer Institute at Emory University. Clinical benefit was defined as complete response, partial response, or stable disease based on RECIST 1.1 criteria. Overall survival(OS) and progression-free survival(PFS) were assessed by Kaplan-Meier method and univariate Cox regression(UVA). Results Of 71.4% were